WO2008084319A3 - 新規核酸 - Google Patents

新規核酸 Download PDF

Info

Publication number
WO2008084319A3
WO2008084319A3 PCT/IB2007/004005 IB2007004005W WO2008084319A3 WO 2008084319 A3 WO2008084319 A3 WO 2008084319A3 IB 2007004005 W IB2007004005 W IB 2007004005W WO 2008084319 A3 WO2008084319 A3 WO 2008084319A3
Authority
WO
WIPO (PCT)
Prior art keywords
micro
nucleic acid
rna
cell
disease caused
Prior art date
Application number
PCT/IB2007/004005
Other languages
English (en)
French (fr)
Other versions
WO2008084319A2 (ja
Inventor
Yoji Yamada
Tatsuya Miyazawa
Tetsuo Yoshida
Haruo Nakano
Kyoko Kosaka
Original Assignee
Kyowa Hakko Kogyo Kk
Yoji Yamada
Tatsuya Miyazawa
Tetsuo Yoshida
Haruo Nakano
Kyoko Kosaka
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kogyo Kk, Yoji Yamada, Tatsuya Miyazawa, Tetsuo Yoshida, Haruo Nakano, Kyoko Kosaka filed Critical Kyowa Hakko Kogyo Kk
Priority to EP07859120A priority Critical patent/EP2123752A4/en
Priority to US12/519,960 priority patent/US20100099746A1/en
Priority to JP2008552924A priority patent/JPWO2008084319A1/ja
Publication of WO2008084319A2 publication Critical patent/WO2008084319A2/ja
Publication of WO2008084319A3 publication Critical patent/WO2008084319A3/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/10—Production naturally occurring

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

本発明により新規な配列を有するマイクロＲＮＡやマイクロＲＮＡ前駆体などの核酸が提供される。本発明の核酸は、マイクロＲＮＡの発現または変異の検出、細胞の分離、標的配列を有する遺伝子の発現抑制、マイクロＲＮＡの機能の促進または抑制させる物質のスクリ－ニング、肥満細胞の異常に起因する疾患、間葉系幹細胞の増殖または分化の異常に起因する疾患、癌及び細胞の増殖異常や組織の過形成等が原因となっている疾患の診断や治療に有用である。
PCT/IB2007/004005 2006-12-18 2007-12-18 新規核酸 WO2008084319A2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP07859120A EP2123752A4 (en) 2006-12-18 2007-12-18 NOVEL NUCLEIC ACID
US12/519,960 US20100099746A1 (en) 2006-12-18 2007-12-18 Novel nucleic acid
JP2008552924A JPWO2008084319A1 (ja) 2006-12-18 2007-12-18 新規核酸

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006-339997 2006-12-18
JP2006339997 2006-12-18

Publications (2)

Publication Number Publication Date
WO2008084319A2 WO2008084319A2 (ja) 2008-07-17
WO2008084319A3 true WO2008084319A3 (ja) 2008-09-25

Family

ID=39609102

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2007/004005 WO2008084319A2 (ja) 2006-12-18 2007-12-18 新規核酸

Country Status (4)

Country Link
US (1) US20100099746A1 (ja)
EP (1) EP2123752A4 (ja)
JP (1) JPWO2008084319A1 (ja)
WO (1) WO2008084319A2 (ja)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2374884A3 (en) * 2006-09-04 2012-01-11 Kyowa Hakko Kirin Co., Ltd. Human miRNAs isolated from mesenchymal stem cells
CN101424640B (zh) * 2007-11-02 2012-07-25 江苏命码生物科技有限公司 血清中微小核糖核酸的检测方法和用于检测的试剂盒、生物芯片及其制作和应用方法
EP2298359A1 (en) * 2008-06-04 2011-03-23 Kyowa Hakko Kirin Co., Ltd. Nucleic acid capable of controlling degranulation of mast cell
GB0906130D0 (en) * 2008-10-03 2009-05-20 Procrata Biosystems Ltd Transcription factor decoys
US8563298B2 (en) 2010-10-22 2013-10-22 T2 Biosystems, Inc. NMR systems and methods for the rapid detection of analytes
AU2011317073B2 (en) 2010-10-22 2016-04-07 T2 Biosystems, Inc. NMR systems and methods for the rapid detection of analytes
US8409807B2 (en) 2010-10-22 2013-04-02 T2 Biosystems, Inc. NMR systems and methods for the rapid detection of analytes
US20140315750A1 (en) * 2011-11-15 2014-10-23 The United States Of America, As Represented By The Secretary, Department Of Health Selective detection of norovirus
EP2839038B1 (en) 2012-04-20 2019-01-16 T2 Biosystems, Inc. Compositions and methods for detection of candida species
US20180201937A1 (en) * 2015-08-04 2018-07-19 The University Of Chicago Inhibitors of cacna1a/alpha1a subunit internal ribosomal entry site (ires) and methods of treating spinocerebellar ataxia type 6
JP2019512208A (ja) 2016-01-21 2019-05-16 ティー２ バイオシステムズ，インコーポレーテッド 細菌を迅速に検出するｎｍｒ法及びシステム
EP4293113A3 (en) * 2016-05-10 2024-04-10 National University Corporation Tokyo Medical and Dental University Expression inhibitor of inflammation promoting factor, screening method for active ingredient thereof, expression cassette useful for said method, diagnostic agent and diagnosis method
AU2018380422A1 (en) * 2017-12-08 2020-06-25 University Of Connecticut Compositions and methods for treating disorders of genomic imprinting
WO2022178411A1 (en) * 2021-02-22 2022-08-25 Alnylam Pharmaceuticals, Inc. Folliculin irna compositions and methods thereof
CN113999852B (zh) * 2021-11-30 2024-04-02 杭州市富阳区第一人民医院 circ_0001772作为结直肠癌诊断和治疗标志物的应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6582908B2 (en) * 1990-12-06 2003-06-24 Affymetrix, Inc. Oligonucleotides
KR100754091B1 (ko) 1995-10-31 2007-08-31 가부시끼가이샤 디나벡 겡뀨쇼 자율 복제 능력을 갖는 (-)쇄 ｒｎａ 바이러스 벡터
CA2236378C (en) 1995-11-01 2011-01-25 Dnavec Research Inc. Recombinant sendai virus
US6468794B1 (en) 1999-02-12 2002-10-22 Stemcells, Inc. Enriched central nervous system stem cell and progenitor cell populations, and methods for identifying, isolating and enriching for such populations
JP2002034580A (ja) 2000-01-05 2002-02-05 Japan Science & Technology Corp 多能性神経系前駆細胞を分離し、精製するための方法および多能性神経系前駆細胞
US20020135539A1 (en) 2001-02-22 2002-09-26 Blundell Barry George Interaction with a volumetric display system
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
US7250496B2 (en) * 2002-11-14 2007-07-31 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
PT2284266E (pt) * 2002-11-14 2013-12-17 Thermo Fisher Scient Biosciences Inc Siarn contra tp53
WO2005024061A2 (en) * 2003-09-03 2005-03-17 Cancer Research Technology Limited Compounds and methods for modulation of dna replication
US20080038819A1 (en) * 2004-03-29 2008-02-14 Haruo Sugiyama Micro Rna Inhibiting the Expression of Wt1 Gene and Utilization of the Same
JP5697297B2 (ja) * 2004-05-14 2015-04-08 ロゼッタ ジノミクス リミテッド マイクロｎａｓおよびその使用
US7635563B2 (en) * 2004-06-30 2009-12-22 Massachusetts Institute Of Technology High throughput methods relating to microRNA expression analysis
US8071306B2 (en) * 2005-01-25 2011-12-06 Merck Sharp & Dohme Corp. Methods for quantitating small RNA molecules
US20080125583A1 (en) * 2005-02-11 2008-05-29 International Business Machines Corporation Ribonucleic acid interference molecules
CA2605701C (en) * 2005-04-29 2015-12-08 Rockefeller University Human micrornas and methods for inhibiting same
US20090215865A1 (en) * 2006-01-10 2009-08-27 Plasterk Ronald H A Nucleic Acid Molecules and Collections Thereof, Their Application and Identification
EP2035446A2 (en) * 2006-06-19 2009-03-18 Københavns Universitet (University of Copenhagen) Ribozyme mediated stabilization of polynucleotides
EP2374884A3 (en) * 2006-09-04 2012-01-11 Kyowa Hakko Kirin Co., Ltd. Human miRNAs isolated from mesenchymal stem cells
EP2090665A2 (en) * 2006-10-20 2009-08-19 Exiqon A/S Novel human microRNAs associated with cancer
US8188255B2 (en) * 2006-10-20 2012-05-29 Exiqon A/S Human microRNAs associated with cancer
EP2298359A1 (en) * 2008-06-04 2011-03-23 Kyowa Hakko Kirin Co., Ltd. Nucleic acid capable of controlling degranulation of mast cell

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
MONTICELLI S. ET AL.: "MicroRNA profiling of the murine hematopoietic system", GENOME BIOL., vol. 6, no. 8, 2005, pages R71, XP021013036 *
MONTICELLI S. ET AL.: "Regulation of gene expression in mast cells: micro-rNA expression and chromatin structural analysis of cytokine genes", NOVARTIS FOUND SYMP., vol. 271, 2005, pages 179 - 190, XP008131548 *
See also references of EP2123752A4 *

Also Published As

Publication number Publication date
EP2123752A4 (en) 2010-08-11
US20100099746A1 (en) 2010-04-22
JPWO2008084319A1 (ja) 2010-04-30
WO2008084319A2 (ja) 2008-07-17
EP2123752A2 (en) 2009-11-25

Similar Documents

Publication Publication Date Title
WO2008084319A3 (ja) 新規核酸
WO2009044899A1 (ja) 細胞の増殖を制御する核酸
WO2008082730A3 (en) Biomarkers of target modulation, efficacy, diagnosis and/or prognosis for raf inhibitors
WO2011082310A3 (en) Methods and compositions for targeted polynucleotide modification
EP2374884A3 (en) Human miRNAs isolated from mesenchymal stem cells
WO2012149468A3 (en) Instruments and methods for the implantation of cell-seeded substrates
EP2426206A3 (en) Selecting and stablizing dsRNA constructs
Müller et al. Mitophagy and mitochondrial dynamics in Saccharomyces cerevisiae
WO2010001169A3 (en) Chemical compounds 251
WO2009091994A3 (en) Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof
WO2008073922A3 (en) Functions and targets of let-7 micro rnas
WO2007109155A3 (en) Assays for detection of antibodies to lysosomal enzymes
WO2011036640A3 (en) Meganuclease reagents of uses thereof for treating genetic diseases caused by frame shift/non sense mutations
WO2007103808A3 (en) Microrna expression profile associated with pancreatic cancer
WO2010062369A3 (en) Methods and compositions for inhibiting clostridium difficile spore germination and outgrowth
WO2006135886A3 (en) Compositions and methods for treating and diagnosing cancer
WO2007030743A3 (en) Cochlear implants containing biological cells and uses thereof
EP1808493A3 (en) Substrates and methods for assaying deubiquitinating enzymes activity
WO2006084242A3 (en) Tissue sensor and uses thereof
WO2007015771A3 (en) Composition and method for introduction of rna interference sequences into targeted cells and tissues
WO2011133960A3 (en) Lysosomal storage disease enzyme
WO2008106594A3 (en) Inhibitors of nucleophosmin (npm) and methods for inducing apoptosis
WO2008130619A3 (en) A composition comprising an inhibitor of pde4 and/or pde7
WO2008098569A3 (de) Biologisch wirksame moleküle, insbesondere auf grundlage von pna und sirna, verfahren zu deren zellspezifischen aktivierung sowie applikationskit zur verabreichung
WO2008107114A3 (de) Kontrollgene zur normalisierung von genexpressionsanalysedaten

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2007859120

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07859120

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2008552924

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 12519960

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE